ALA arovella therapeutics limited

Relapse rate of Auto CD19 CAR T

  1. 2,344 Posts.
    lightbulb Created with Sketch. 347
    From the below presentation 60%-65% of the current on-market (auto) treatments will relapse. https://hotcopper.com.au/threads/ann-ceo-presentation-to-the-egm.7602671/
    upload_2023-10-15_9-13-31.png
    That's one reason why Michael and Mini were impressed with the ability of iNKT cell secondary remission characteristics (37' 34" in this).

    The IMU Azer-Cel acquisition used in conjunction with its onCarlytics platform could be quite successful. An indication of how successful will be the ALA101/onCarlytics in vivo trial results which are pending this quarter.Personally I can't see why IMU would have gone down the Azer-Cel acquisition pathway if they didn't already know that indicative results from the ALA trial were trending positively.
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
9.5¢
Change
0.015(18.8%)
Mkt cap ! $113.6M
Open High Low Value Volume
8.1¢ 9.5¢ 8.1¢ $182.2K 2.104M

Buyers (Bids)

No. Vol. Price($)
1 141934 9.5¢
 

Sellers (Offers)

Price($) Vol. No.
9.7¢ 100000 1
View Market Depth
Last trade - 16.10pm 16/09/2025 (20 minute delay) ?
ALA (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.